Posted on by Update Media Group
Well-characterised biospecimens assist development of cancer immunotherapies
Amsbio report how its biospecimens were used in a large-scale immuno-oncology study analysing Fibroblast Activation protein (FAP) expression across 23 tumour types, contributing to new insights into biomarker development for cancer immunotherapies. Scientists at Roche Pharma Research used both immunohistochemistry and RNA sequencing techniques to assess expression patterns. The study highlights the value of top-quality human tumour samples for translational immunology research in complex tumour…









